On the Front Lines Vs. COVID: Gilead, Moderna Prepare to Report Q2 Earnings
Key Takeaways Earnings numbers less important than coronavirus progress for MRNA and GILD MRNA could update on vaccine, while GILD treatment progress eyed Timing on vaccine, possible new drug formulation among possible highlights Ahead of earnings from two of the most closely watched biotechs—Moderna (MRNA) and Gilead (GILD)—one thing seems pretty certain: Investors are likely […]